NCT05808010|Unknown
Loading search results
Sponsor study identifier
interventional
60
1 country
1
Study Start
June 7, 2023
Actual (reported)Primary Completion
April 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
April 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
To evaluate the efficacy and safety of umbilical cord blood mononuclear cells in the treatment of chronic atrophic gastritis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 17, 2023
Actual (reported)April 11, 2023
Actual (reported)June 7, 2023
Actual (reported)April 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
April 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Change from baseline OLGA/OLGIM stages of gastric mucosa
Assessment of OLGA/OLGIM stages by GI pathologists. The obtained biopsy specimens will be scored using visual analogue scale (0, 1, 2, 3 points for none, mild, moderate and severe, respectively) to evaluate gastroatrophy and gastrointestinal metaplasia
At the first, seventh and thirteenth month of treatment
Change from baseline gastric mucosal status under gastroscope
Assessment of Kimura-Takemoto classification by endoscopy. The variation of atrophy can reflect the extent and degree of atrophy. The severity of atrophy increases gradually with C1-C2-C3-O1-O2-O3. Cases of closed-type gastric mucosa atrophy have an atrophic boundary between the fundic mucosa and the pyloric mucosa in the antrum or less curvature of the gastric body. Cases of open-type gastric mucosa atrophy have an atrophic boundary in the lateral wall or greater curvature of the gastric body. C, closed; O, open
At the first, seventh and thirteenth month of treatment
Change from baseline blood test result
At the first, seventh and thirteenth month of treatment
Incidence of adverse reactions
Through follow-up period completion, an average of 1 year
Mononuclear cells are obtained from umbilical cord blood by density gradient centrifugation
2 times gastric submucosal injection of mononuclear cells (10\^8) at 1 month interval
Orally delivered tablets for 7 months. Take it according to the instructions.
Shandong Provincial Hospital
Jinan, Shandong, 250021, China
hongwei Xu, MD
Shandong Provincial Hospital
First Submitted
March 17, 2023
First Posted
April 11, 2023
Study Start
June 7, 2023
Actual (reported)Primary Completion
April 2025
Estimated (date passed)Multi-omics Analyses on Etiology and Early Detection of Stomach Cancer Precursor Lesions
Weifuchun is a kind of edible Chinese herbal prescription
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
April 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
April 17, 2024
Record last verified: 2024-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: